<DOC>
	<DOCNO>NCT00280150</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth non-small cell lung cancer block blood flow tumor . Radiation therapy use high energy x-ray kill tumor cell . Erlotinib may stop growth tumor cell block enzymes need cell growth . Giving combination chemotherapy together bevacizumab , radiation therapy , erlotinib may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose bevacizumab erlotinib give together combination chemotherapy radiation therapy see well work treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy , Bev , RT , Erlotinib Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose bevacizumab erlotinib hydrochloride give together carboplatin , paclitaxel , thoracic conformal radiotherapy patient stage IIIA IIIB non-small cell lung cancer . ( Phase I [ close accrual 1/3/2008 ] ) - Determine safety toxicity profile regimen patient . ( Phase I [ close accrual 1/3/2008 ] ) - Determine progression-free survival patient treated induction therapy comprise carboplatin , paclitaxel , bevacizumab follow chemoradiotherapy comprise thoracic conformal radiotherapy , carboplatin , paclitaxel , bevacizumab , erlotinib hydrochloride consolidation therapy comprise bevacizumab erlotinib hydrochloride . ( Phase II ) - Determine overall toxicity profile regimen patient . ( Phase II ) Secondary - Determine response rate patient treat induction therapy comprise carboplatin , paclitaxel , bevacizumab . ( Phase I [ close accrual 1/3/2008 ] II ) - Determine toxicity profile induction therapy patient . ( Phase I [ close accrual 1/3/2008 ] II ) - Determine overall response rate survival profile patient treated regimen . ( Phase I [ close accrual 1/3/2008 ] II ) - Determine feasibility tolerability administer consolidation therapy comprise erlotinib hydrochloride bevacizumab treatment combine modality therapy ( induction therapy chemoradiotherapy ) patient . ( Phase I [ close accrual 1/3/2008 ] II ) - Collect tumor blood sample patient future analysis correlation molecular marker clinical benefit . ( Phase I [ close accrual 1/3/2008 ] II ) OUTLINE : This nonrandomized , open-label , control , phase I ( close accrual 1/3/2008 ) , dose-escalation study bevacizumab erlotinib hydrochloride , follow phase II study . - Phase I ( close accrual 1/3/2008 ) : - Induction therapy : Patients receive paclitaxel IV 3 hour , carboplatin IV 15-30 minute , bevacizumab IV 30-90 minute day 1 . Treatment repeat every 21 day 2 course . Patients stable respond disease proceed chemoradiotherapy . - Chemoradiotherapy : Patients receive chemoradiotherapy accord assign dose cohort : - Cohort 1 : Patients undergo thoracic conformal radiotherapy ( TCRT ) day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 . Patients also receive carboplatin IV paclitaxel IV day 1 , 8 , 15 , 22 , 29 , 36 , 43 bevacizumab IV 30-90 minute day 1 , 15 , 29 , 43 . - Cohort 2 : Patients undergo TCRT receive carboplatin , paclitaxel , bevacizumab cohort 1 . Patients also receive oral erlotinib hydrochloride day 2-5 , 9-12 , 16-19 , 23-26 , 30-33 , 37-40 , 44-47 . - Cohort 3 : Patients undergo TCRT receive carboplatin , paclitaxel , bevacizumab cohort 1 . Patients also receive high dos oral erlotinib hydrochloride day 2-5 , 9-12 , 16-19 , 23-26 , 30-33 , 37-40 , 44-47 . Cohorts 5 patient receive chemoradiotherapy describe maximum tolerated dose ( MTD ) determine . The MTD define dose precede 2 ( grade 4 toxicity ) 3 ( grade 3 toxicity ) 5 patient experience dose-limiting toxicity . Three 6 week completion chemoradiotherapy , patient proceed consolidation therapy . - Consolidation therapy : Patients receive bevacizumab IV day 1 oral erlotinib hydrochloride day 1-21 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . - Phase II : - Induction therapy : Patients receive induction therapy phase I ( close accrual 1/3/2008 ) . - Chemoradiotherapy : Patients undergo TCRT receive carboplatin paclitaxel phase I ( close accrual 1/3/2008 ) . Patients also receive bevacizumab erlotinib hydrochloride phase I ( close accrual 1/3/2008 ) MTD/drug combination determine phase I ( close accrual 1/3/2008 ) . - Consolidation therapy : Patients receive consolidation therapy phase I ( close accrual 1/3/2008 ) . Tumor tissue peripheral blood collect baseline future correlative biomarker study . After completion study therapy , patient follow every 2 month 2 year , every 4 month 2 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonsmall cell lung cancer Stage IIIA IIIB disease No malignant pleural pericardial effusion No palpable supraclavicular adenopathy Squamous cell histology allow provided hemoptysis central invasive lesion abut invade major blood vessel chest ( without cavitation ) Considered suitable appropriate combine modality therapy thoracic conformal radiotherapy , determine treat medical radiation oncologist PATIENT CHARACTERISTICS : ECOG performance status 01 Hemoglobin ≥ 9.0 mg/dL Platelet count ≥ 100,000/mm³ ANC ≥ 1,500/mm³ FEV_1 ≥ 1 L Creatinine ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Bilirubin normal PTT INR normal Urine protein : creatinine ratio &lt; 1.0 Blood pressure ≤ 150/100 mm Hg 3 separate occasion Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant recent hemoptysis ( &gt; ½ teaspoon bright red blood ) No unstable angina No NYHA congestive heart failure ≥ class II No myocardial infarction stroke within past 6 month No clinically significant peripheral vascular disease No evidence bleed diathesis coagulopathy No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No serious , nonhealing wound , ulcer , bone fracture No thrombosis require therapeutic anticoagulation No significant traumatic injury within last 28 day PRIOR CONCURRENT THERAPY : Recovered prior surgery At least 4 week since prior concurrent participation another experimental drug study At least 4 week since prior concurrent major surgical procedure open biopsy At least 2 week since prior mediastinoscopy mediastinotomy At least 1 week since prior fine needle aspiration core biopsy No concurrent antineoplastic antitumor agent , include chemotherapy , radiotherapy , immunotherapy , hormonal anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>